Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002317237 | SCV000670513 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-12-09 | criteria provided, single submitter | clinical testing | The p.A1881V variant (also known as c.5642C>T), located in coding exon 38 of the NF1 gene, results from a C to T substitution at nucleotide position 5642. The alanine at codon 1881 is replaced by valine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000632437 | SCV000753618 | likely benign | Neurofibromatosis, type 1 | 2024-04-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000681199 | SCV000808658 | uncertain significance | not provided | 2023-10-09 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000632437 | SCV002560900 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004569228 | SCV005052318 | uncertain significance | Juvenile myelomonocytic leukemia | 2023-11-29 | criteria provided, single submitter | clinical testing |